DNA Genetic Engineering Genetics Scientist 
The Pharma Data
JANUARY 4, 2021
But scientists at the University of California (UC), Santa Barbara, believe fluoride may offer hope in the fight against antibiotic-resistant bacteria. The UC Santa Barbara research uses a method that addresses not only antibiotic overuse, but also the containment of genetically modified organisms (GMOs). “If ” Source link.
Drug Discovery World
JULY 5, 2023
A fulfilling part of my job is meeting the scientists, companies, and institutions at the forefront of ground-breaking research that are advancing patient health outcomes. MG: I meet regularly with the brilliant European scientists driving cutting edge global cancer research. Biography Mark Garner received his Ph.D.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
NOVEMBER 17, 2022
The rapidly growing area of synthetic biology – including molecular biology, biotechnology, biophysics, and genetic engineering – is having a marked impact on the drug discovery landscape. Lu Rahman selects some recent synthetic biology innovations and the potential they hold to benefit drug discovery. .
Drug Discovery World
JUNE 27, 2024
Scientists at the University of Sydney have developed a gene-editing tool with greater accuracy and flexibility than CRISPR. SeekRNA uses a programmable ribonucleic acid (RNA) strand that can directly identify sites for insertion in genetic sequences, simplifying the editing process and reducing errors. This can introduce errors.
Drug Discovery World
FEBRUARY 14, 2024
While a typical chemisty, manufacturing and controls (CMC) timeline from DNA to Investigational New Drug (IND) application in 2015 would have been approximately 24 months, by 2023 the same pathway was expected to take only 10 months.
pharmaphorum
SEPTEMBER 13, 2022
During this period, Nobel prize-winning German scientist Paul Ehrlich developed his lock-key hypothesis of molecules that specifically bind to cell receptors. Building on the success of cytokine-based immunotherapies, scientists continued to seek other areas where the immune system could be leveraged against tumours.
Drug Discovery World
NOVEMBER 9, 2023
Klaus Wagenbauer, PhD, Founder & CEO, Plectonic, on: ‘Programmable DNA-origami-based T cell engagers: PTE’. Gail Calvert, Field Application Scientist, Sartorius UK, on: ‘Leveraging integrated and advanced technologies for successful cell line development’.
Expert insights. Personalized for you.
52 
Let's personalize your content